Affimed (NASDAQ:AFMD) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Affimed (NASDAQ:AFMD) in a research report report published on Tuesday,Benzinga reports. Cantor Fitzgerald also issued estimates for Affimed’s FY2024 earnings at ($4.06) EPS.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Friday, November 15th. Stifel Nicolaus reduced their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Affimed presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Price Performance

NASDAQ:AFMD opened at $2.62 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $4.45. Affimed has a one year low of $2.61 and a one year high of $8.95.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. As a group, analysts anticipate that Affimed will post -3.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Affimed during the 3rd quarter valued at $44,000. Choreo LLC bought a new position in shares of Affimed during the 2nd quarter valued at $54,000. FMR LLC grew its holdings in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Intellectus Partners LLC grew its holdings in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.